Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The ACUITY trial: a randomized comparison of Angiomax (Bivalirudin) versus heparin (unfractionated heparin or enoxaparin) in patients undergoing early invasive management for acute coronary syndromes without ST-segment elevation

Trial Profile

The ACUITY trial: a randomized comparison of Angiomax (Bivalirudin) versus heparin (unfractionated heparin or enoxaparin) in patients undergoing early invasive management for acute coronary syndromes without ST-segment elevation

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bivalirudin (Primary) ; Abciximab; Enoxaparin sodium; Enoxaparin sodium; Eptifibatide; Heparin; Tirofiban
  • Indications Acute coronary syndromes
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ACUITY
  • Sponsors The Medicines Company
  • Most Recent Events

    • 25 Sep 2023 Results of Individual Patient Data Meta-Analysis , from MATRIX, VALIDATE-SWEDEHEART, ISAR-REACT 4, ACUITY and BRIGHT; comparing the outcomes of bivalirudin and heparin in patients with non-ST-segment-elevation myocardial infarction undergoing PCI, published in the Circulation
    • 20 Apr 2016 Results of a pooled analysis from REPLACE-2, ACUITY and HORIZONS-AMI Trials (n=3641) published in the American Journal of Cardiology
    • 01 Dec 2015 Results(n=14,784) of pooled analysis of this and other two trials (see profile 21574 and 266431) published in the American Journal of Cardiology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top